If left undiagnosed and untreated for a prolonged period, fatty liver disease can progress to more serious conditions, such as cirrhosis and liver cancer.
All over the United States, countless research projects designed to improve outcomes have lost funding or been shut down. Even screening efforts targeting patients in impoverished communities have been impacted by these policies.
The first 250 patients has been enrolled in the CORCINCH-HF U.S. pivotal trial evaluating the AccuCinch Transcatheter Left Ventricular Restoration System in patients with HFrEF.
Avidity Biosciences, a San Diego-based biopharmaceutical company, is expanding its ongoing collaboration with Bristol Myers Squibb to identify new cardiovascular therapies.
Their goal is to shape the future of medical imaging, enhance the standard of care, and improve patient outcomes by incorporating advancements in AI and digital solutions.
Researchers evaluated two techniques for predicting PPM after TAVR, comparing them to how cardiologists typically check for PPM in day-to-day practice.